Latest Bls Pharmaceuticals (ASX:BLS) News

Small-cap shares produced another uneven week, led by a major fall in Corporate Travel Management and strong gains in energy, gas and takeover stocks.
Investors rewarded rising profits and new deals, but sold several companies despite promising project news.

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Small-cap shares produced the week’s biggest moves, led by Xenitra’s 60% surge and Carnaby Resources’ takeover jump.
Mining news dominated, but sharp falls in Lotus Resources and several funded developers showed that new capital can still unsettle investors.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.